For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Retatrutide
Weight & Metabolicphase_2_3

Retatrutide

GLP-3 RT
Weight & Metabolic · CAS 2381089-83-2
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
B
PubMed records
158
Female-tagged
20
Sex-analysis
2
CAS
2381089-83-2
B
Evidence grade B, Phase 2/3 human trial evidence across 158 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Retatrutide: of 158 PubMed records, 20 are tagged as including female subjects and 2 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Retatrutide is an investigational triple receptor agonist that engages the GIP, GLP-1, and glucagon receptors within a single molecule, positioning it among the newer multi-agonist compounds in metabolic research. It is not an approved drug and remains in Phase 2 stage clinical development.

Retatrutide has been studied for its combined incretin and glucagon pharmacology, in which appetite- and glucose-related signaling from the GIP and GLP-1 receptors is paired with glucagon-driven energy-expenditure pathways. It has been investigated in obesity- and metabolism-focused research models as a way to examine how simultaneous agonism of three receptors influences energy balance and glucose handling.

What makes retatrutide notable for a weight and metabolic catalog is its triple-agonist design, which contrasts with the single- and dual-agonist compounds that preceded it. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 2 development for obesity. Its early trials enrolled substantial numbers of women, but it is not approved and long-term, female-specific safety data does not yet exist.

Evidence in women

Menstrual cycle
Unstudied
No menstrual cycle interaction data.
Pregnancy & lactation
Contraindicated
Investigational with no pregnancy or lactation safety data. Avoid; there is no basis to consider it safe.
Hormonal interactions
Unstudied
Oral-contraceptive interaction has not been characterized. As a GLP-1-containing agent that delays gastric emptying, an effect on oral drug absorption is plausible but unstudied for this compound.
Perimenopause & menopause
Unstudied
No data in perimenopausal or menopausal populations.
Sex differences
No evidence
In the indexed literature, many studies included women (Phase 2 obesity trials enrolled women well), but few reported sex-stratified outcomes.

Mechanism

A single molecule agonizing the GIP, GLP-1, and glucagon receptors, combining appetite and glucose effects with glucagon-driven energy expenditure.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Investigational; no established dose. Trial doses only.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: pregnancy (investigational, avoid); not approved for any use

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitingdiarrheadecreased appetite

Retatrutide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Retatrutide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Retatrutide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Retatrutide?

Retatrutide, also known as GLP-3 RT, is a research compound in our weight metabolic category. Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 2 development for obesity.

Is Retatrutide studied in women?

Retatrutide: of 158 PubMed records, 20 are tagged as including female subjects and 2 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Retatrutide been studied during pregnancy or breastfeeding?

Contraindicated. Investigational with no pregnancy or lactation safety data. Avoid; there is no basis to consider it safe. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Retatrutide have, and why?

Retatrutide carries evidence grade B. Phase 2/3 human trial evidence across 158 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Retatrutide?

No. A female-specific dose for Retatrutide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Retatrutide administered in research?

In the published literature, Retatrutide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Retatrutide?

Effects reported in the research literature include nausea, vomiting, diarrhea, decreased appetite. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Retatrutide?

The CAS registry number for Retatrutide is 2381089-83-2. It is also referred to as GLP-3 RT, triple agonist, LY3437943. Use it to confirm identity against a Certificate of Analysis.

How should Retatrutide be stored and handled?

Retatrutide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Retatrutide for research?

For laboratory research use, Retatrutide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Retatrutide at Aurevena Research
Research-use supplier: Retatrutide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

37356331 · 37738562

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.